<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213172</url>
  </required_header>
  <id_info>
    <org_study_id>14PIHL</org_study_id>
    <nct_id>NCT02213172</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome</brief_title>
  <acronym>14PIHL</acronym>
  <official_title>Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome: an 8-Week, Randomized, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lallemand Health Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if two different probiotic strains, Lactobacillus
      paracasei HA-196 and Bifidobacterium longum R0175, are effective in helping subjects manage
      the symptoms of IBS
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2014</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">February 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IBS Symptom Severity Score</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Assessed using IBS Severity Scoring System Questionnaire, Part I.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IBS Symptom Severity Score by IBS Subtype</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed using IBS Severity Scoring System Questionnaire, Part I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders</measure>
    <time_frame>8 weeks</time_frame>
    <description>A responder is defined as a participant who has at least a 20% improvement in the IBS-SSS severity score after 8 weeks of supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and Depression</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed by administering the HADS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal pain frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed using IBS Severity Scoring System Questionnaire, Part I(c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal distension/tightness</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed using the IBS-SSS Question 2(b)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Pain Intensity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean weekly score. Assessed using IBS-SSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of straining</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed using IBS daily diary, 5 point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed by administration of the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of IBS symptoms on Quality of Life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed by administration of the IBS-QOL Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of IBS Symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>Assessed by administration of the IBS-SSS questionnaire, difference from baseline to week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Habit Satisfaction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed by question 3 of the IBS-SSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed using the Bristol Stool Scale included in the IBS Daily Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed using the IBS Daily Diary</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compliance and Recovery of Probiotic strains</measure>
    <time_frame>8 weeks</time_frame>
    <description>Monitored by qPCR of fecal samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Microbiome Composition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Detected in fecal samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Cysteine and serine-protease activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured in stool samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Amount of rescue medication used throughout the trial</measure>
    <time_frame>8 weeks</time_frame>
    <description>Use of rescue medication (Bisacodyl 5mg tablet)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Anthropometric Measurements</measure>
    <time_frame>8 weeks</time_frame>
    <description>Blood pressure, Heart rate, Weight and BMI</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety blood parameters</measure>
    <time_frame>8 weeks</time_frame>
    <description>Complete blood count, electrolytes, markers of kidney and liver function</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Adverse Events occurring throughout the trial</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Irritable Bowel Syndrome-Constipation</condition>
  <arm_group>
    <arm_group_label>Bifidobacterium longum R0175</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus paracasei HA-196</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium longum R0175</intervention_name>
    <arm_group_label>Bifidobacterium longum R0175</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus paracasei HA-196</intervention_name>
    <arm_group_label>Lactobacillus paracasei HA-196</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged 18 years and older.

          -  IBS diagnosis according to Rome III criteria and referral to this study by a
             clinician. That is, recurrent abdominal pain or discomfort (i.e., uncomfortable
             sensation other than pain) at least 2 days/month in the last 3 months (response to
             question 1 of the IBS Rome III module questionnaire &gt; 2) associated with 2 or more of
             the following:

               -  Improvement with defecation (response to question 4 of the IBS Rome III module
                  questionnaire &gt; 0);

               -  Onset associated with a change in stool frequency (response to question 5 or 6 of
                  the IBS Rome III module questionnaire &gt; 0);

               -  Onset associated with a change in stool form (appearance). (response to question
                  7 or 8 of the IBS Rome III module questionnaire &gt; 0).

          -  For women, the abdominal pain or discomfort should be experienced during days other
             than menstrual bleeding (response to question 2 of the IBS Rome III module
             questionnaire = 0 or 2)

          -  Criterion must be fulfilled for the last 3 months with symptom onset at least 6 months
             prior to screening (response to question 3 of the IBS Rome III module questionnaire =
             1).

          -  A copy of the IBS module is provided in Appendix A: IBS Rome III Module Questionnaire

          -  Participants from the general population who have IBS symptoms, without a previous
             diagnosis, will be assessed by the Principle Investigator and included in the study if
             differential diagnosis confirms IBS. The Principle Investigator will confirm the
             diagnosis of IBS in any potential participants who have a previous diagnosis of IBS.

          -  Subjects experiencing a pain/discomfort frequency of at least 2 days a week during the
             run-in period. At visit 2, subjects will be asked &quot;In the last 2 weeks, how often each
             week did you have discomfort or pain anywhere in your abdomen? &quot;. The answer must be
             at least 2.

          -  Subjects diagnosed with IBS who have depression may be included

          -  Absence of black color (melena) or blood in stools.

          -  Willingness to complete questionnaires, records, and diaries associated with the study
             and to complete all clinic visits.

          -  Willingness to discontinue consumption of probiotics (e.g. yogurts, with live, active
             cultures or supplements).

          -  Able to provide informed consent.

        Exclusion Criteria:

          -  Subjects with a history of suicidal ideation, or current suicidal ideation

          -  Previous history of gastrointestinal surgery (except appendectomy, cholecystectomy,
             hernia repair, or hemorrhoidectomy).

          -  Other gastrointestinal diseases (except hemorrhoids and uncomplicated diverticula), as
             assessed by ultrasonography, colonoscopy, or rectoscopy, or history of Clostridium
             difficile-associated diarrhea.

          -  A family history (immediate family i.e. siblings and parents) of colorectal cancer,
             inflammatory bowel disease and/or celiac spruce.

          -  Co-existing organic gastrointestinal disease.

          -  Presence of rectal bleeding, recent weight loss (greater than 5 kg in the past month)
             or iron deficiency anemia.

          -  History of, or current diagnosis of, liver disease, kidney disease, pulmonary disease,
             cardiovascular disease, pancreatic disease, any cancer.

          -  Presence of immune-compromised conditions such as AIDS, lymphoma or undergoing
             long-term corticosteroid treatment

          -  Presence or history of neurological disorders, or significant psychiatric illness.

          -  History of, or current diagnosis of, pelvic floor dyssynergia.

          -  Positive drug or alcohol screen or recent history of drug or alcohol abuse (within 3
             years of screening).

          -  Milk or soy allergy.

          -  Use of another investigational product within 3 months of the screening visit. The
             screened participant could be eligible to participate after a washout period.

          -  Positive pregnancy test in women of child-bearing potential.

          -  Pregnant or breast-feeding or planning on becoming pregnant.

          -  Women of child-bearing potential not using effective contraception. Acceptable methods
             of birth control include:

               -  Hormonal contraceptives including oral contraceptives, hormone birth control
                  patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable
                  contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)

               -  Intrauterine devices

               -  Vasectomy of partner (shown successful as per appropriate follow-up)

               -  Double barrier method (use of physical barrier by both partners)

          -  Use of any antibiotic drug (e.g., neomycin, rifaximin) within 1 month of screening.
             The screened participant could be eligible to participate after a 1 month washout
             period.

          -  Use of PPI or H2R antagonist within 1 month of screening. The screened participant
             could be eligible to participate after a 1 month washout period.

          -  Daily use of non-steroidal anti-inflammatory drugs, cortisone, or other
             anti-inflammatory drugs 1 month prior to screening. The screened participant could be
             eligible to participate after a 1 month washout period.

          -  Current use, or use within the past 1 month, of narcotics or other medications for IBS
             symptom management (e.g. alosetron, tegaserod, lubiprostone, antispasmodics,
             antidiarrheals, laxatives, antipsychotics, tricyclic anti-depressants, selective
             serotonin reuptake inhibitors (SSRIs)). Subjects taking a stable dose of
             anti-depressants for at least 30 days with no plan to change dosage during the trial
             will be eligible for inclusion in the study.

          -  Regular use of anti-diarrhea medications and laxatives. Occasional use is permitted
             prior to screening (≤ than once a month); if current use is &gt;once per month a one
             month wash out period is needed prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Constipation</keyword>
  <keyword>Bifidobacterium longum</keyword>
  <keyword>Lactobacillus paracasei</keyword>
  <keyword>Lallemand Health Solutions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

